Fountain Therapeutics inks new $6m finance deal

Latest articles

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

VIDEO: The Science of Ovarian Longevity

Instead of papering over the cracks of declining fertility and the effects of menopause, what else can we do to help the longevity of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Ovarian aging – it’s time to menopause for thought

It's World Menopause Day – time to focus on the future of ovarian longevity, not dwell in the present. World Menopause Day is held every...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

Researchers find warning signs for dementia in the blood

Levels of certain microRNAs indicate risk for cognitive decline. Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the...

Click the globe for translations.

New funding for AI and computer vision Longevity drug discovery start-up.

The saying goes: “Some people drink from the fountain of knowledge. Others just gargle.” Well, Fountain Therapeutics will certainly be looking to drink deeply following a multi-million dollar funding injection to further the development of therapies to reverse cellular age.

The biopharmaceutical company is creating a pipeline of therapeutics to treat age-related diseases by reversing cellular age. Fountain Therapeutics uses a transformative platform combining cellular models of aging with the latest in AI and computer vision in order to identify novel targets and potential therapeutics to advance the treatment of age-related health conditions. The new funding stream will be used to bring on board new knowledge and expertise by expanding the already impressive leadership team. 

Proceeds will also be used to advance the novel therapeutics which are identified by the team through preclinical testing in animal models. 

The closure of the latest round of $6m Series A-1 financing brings Fountain Therapeutics’ total Series A funding to $11m. This round was led by Khosla Ventures, along with participation from Nan Fung Life Sciences. Fountain had previously closed on a $5m Series A financing with Nan Fung Life Sciences back in May 2018. 

Fountain Therapeutics’ CEO John Dimos, Ph.D said the funding demonstrated clear support and confidence in the firm’s technology platform and experienced team. Also on the leadership team are co-founders Thomas Rando, M.D, Ph.D, who is a professor of neurology and neurological sciences at Stanford University School of Medicine, Joseph Rodgers, Ph.D, who has extensive experience in the field of aging biology, and Tom Cheung, Ph.D, whose research at the Hong Kong University of Science and Technology aims to increase understanding of adult stem cell function in the context of tissue regeneration, disease and aging. Fountain has also attracted a raft of high-profile scientists, advisors, chemists and engineers.

“Over the last two years, we have built and validated our platform technology, which includes an AI-based drug screening platform and animal models for disease modeling and preclinical testing,” added Dr Dimos. “Today, thanks to the help of our investors, we are in a strong financial position to rapidly discover and develop a pipeline of novel therapeutics to target and reverse the biological process of aging with the potential to improve the quality of life for our aging population.”

Meanwhile, Dr Rando said that, having worked in the field of aging research for more than two decades, he was now confident that there was enough scientific evidence to “demonstrate that aging itself can be approached therapeutically to improve quality of life.”

He added: “Fountain’s technology allows us to solve the challenges of aging with an unbiased and phenotypic-driven approach. This, together with the outstanding team of experts in aging research, places the company in a unique position to reveal new possibilities and radically transform the landscape of drug discovery and development for the treatment of age-related health conditions.”

The new funding should help Fountain to advance its technologies, techniques and understanding of how cells age in order to create therapies to help us live not just longer lives, but to be able to have a higher quality of life for a longer period of time.

As Fountain cell biologist Jessica Johnson sums up perfectly: “Imagine not having to live our later years with the toll that aging takes on our health.”

Image courtesy of Fountain Therapeutics

 

 

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

$70m collaboration to redefine aging research

Astera Institute and Buck Institute announce $70 million collaboration to redefine the field of research on aging. The Buck Institute for Research on Aging and...

Rejuveron leads €15.7m series B in Rejuvenate Biomed

Investment in Rejuvenate Biomed set to accelerate clinical development of its sarcopenia treatment for healthy aging. Rejuveron Life Sciences, a Zürich-based biotechnology company developing therapies...

Maximon launches 100 million Longevity Co-Investment Fund

The Longevity Co-Investment Fund finances longevity-focussed start-up companies launched by company-builder Maximon. Switzerland-based Maximon has announced the launch of its Longevity Co-Investment Fund (LCIF),...

NOVOS – from stealth to oversubscription and beyond

NOVOS is dreaming big to improve health, quality of life and lifespan all at the same time. Last week we covered NOVOS' $3.15 million pre-seed...

Longevity start-up NOVOS closes $3.15m financing round

Successful round for NOVOS sees longevity supplement company raise $3.15 million pre-seed to further its aim to extend healthy human lifespan with science-based supplements. NOVOS,...